title: [Allogenic bone marrow graft in thalassemia major. The French experience].
abstract: From August 1985 to April 1988, 17 patients have been allografted in France for TM. Fourteen (82%) are alive, 10 (58%) are cured and 4 in autologous reconstitution. Three died, 2 of whom after a second transplantation, and 2 due to CMV interstitial pneumonia. Ten of 17 were conditioned by cyclophosphamide (Cy: 200 mg/kg) and busulfan (Bu: 14 mg/kg): 10 are alive, 6 cured and 4 in autologous reconstitution. Five received Cy (200 mg/kg) Bu (16 mg/kg) +/- total lymphoid irradiation (TLI) (3 patients): 2 patients are cured (one after hepatic veno-occlusive disease), and 3 died. For 2 patients, conditioning included total body irradiation: both are cured. Graft versus host (GVH) reaction prevention included: 4 T cell depletion (with additional prevention in 3; 2 are cured, one is in autologous reconstitution, 1 died); 5 cyclosporine alone (2 cured, 2 autologous reconstitution, 1 dead) and 8 cyclosporine + methotrexate (6 cured, 1 autologous reconstitution, 1 dead). Four of 12 evaluable patients presented a less than or equal to 2 grade acute GVHd. None had received a T cell depleted marrow. Bone marrow transplantation is the only curative treatment currently available for TM patients with HLA identical donors. It should be proposed to any young patient before iron overload is established. Optimal conditioning includes Cy (200 mg/kg) + Bu (14 mg/kg). The best protocol for GVHd prevention remains to be defined.
authors.affiliation: Groupe d'Etude des Greffes de Moelle Osseuse.
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
authors.forename: G
authors.initials: G
authors.lastname: Souillet
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
authors.forename: F
authors.initials: F
authors.lastname: Demeocq
authors.forename: A
authors.initials: A
authors.lastname: Fischer
authors.forename: P
authors.initials: P
authors.lastname: Lutz
authors.forename: J P
authors.initials: JP
authors.lastname: Bergerat
authors.forename: P
authors.initials: P
authors.lastname: Herve
authors.forename: F
authors.initials: F
authors.lastname: Freycon
mesh_terms: D000293:Adolescent; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003524:Cyclosporins / Q000627:therapeutic use; D005500:Follow-Up Studies; D005602:France; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D013789:Thalassemia / Q000601:surgery*; D014184:Transplantation, Homologous
chemical_list: D003524:Cyclosporins; D011241:Prednisone
vernacular_title: Greffe allogénique de moelle pour la thalassémie majeure. L'expérience française.